{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized and treated Part 2 participants only","reportingStatus":"POSTED","timeFrame":"From first dose of study drug in Part 2, up to approximately 69 months","title":"Part 2: Number of Participants With Serious TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}